Outcomes in Spontaneous and ART Twin Pregnancies

July 20, 2018 updated by: Shahla Alalaf, Hawler Medical University

Maternal and Perinatal Outcomes in Spontaneous Twins Versus Twins Conceived by Ovulation Induction and Assisted Reproductive Techniques: A Cross Section Study Within One Year

During the last decades, assisted reproductive technique has been transformed from a miracle to real and has become widely used for treatment human infertility.

this was associated with increased the rate of twin pregnancies

Study Overview

Detailed Description

Twin pregnancies are associated with an increased risk of maternal mortality & morbidity and an increase in the incidence of neonatal morbidity and mortality compared to singleton pregnancy.

The heterogeneous results reported so far can also depend on differences in the studied populations and/or in the management approach to twin pregnancy, variability in data regarding neonatal and maternal outcomes.

Evidence on pregnancy outcomes of twins conceived by artificial reproductive technology (ART) compared with those naturally conceived (NC) is conflicting, A 2004 systematic review and a large 2008 study both were praised that in cases of twin pregnancy after assisted conception the perinatal mortality is significantly lower, when compared with those spontaneously conceived .

Study Type

Observational

Enrollment (Actual)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Kurdistan Region
      • Erbil, Kurdistan Region, Iraq, 44001
        • Kurdistan Board for Medical speciality

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Twin delivery was identified when coming to outpatient clinic & labour ward into two groups, first group iatrogenic conceived twins (either ART, or medical ovulation induction mainly clomiphene citrate and gonadotrophins).The second group is a twin pregnancy who conceived naturally .

Demographic characters, maternal and neonatal outcomes were compared in both groups

Description

Inclusion Criteria:

  • Twin delivered >24-week gestational age
  • weight ≥ 500g
  • Diachronic diamniotic twins.

Exclusion Criteria:

  • Intrauterine fetal deaths
  • Higher-order multiple pregnancies
  • Deliveries complicated by early vanishing fetuses
  • Twin pregnancies reduced to singleton
  • Triple pregnancy reduced to twin.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Cross-Sectional

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Maternal diabetes using glucose tolerance test
Time Frame: up to 7 days postpartum
The diagnosis of GDM was based a fasting plasma glucose level of ≥5.6 mmol/L with 2 h plasma glucose level of ≥7.8 mmol/L
up to 7 days postpartum
Hypertension during pregnancy and preeclampsia diagnosed using ACOG guideline a) weight in kilogram b) Apgar score in first and 10th minutes c)Admission to neonatal intensive acre unit measured in days
Time Frame: up to 1 week postpartum
Systolic and diastolic blood pressure equal or more than140/90 mm Hg measured on two or more occasions after 20 weeks of gestation in previously normotensive women, with or without proteinuria (proteinuria of >100 mg/dL by urine analysis, or >300 mg/24 h)
up to 1 week postpartum
Maternal anemia using WHO criteria
Time Frame: up to 1 week
Hemoglobin level less than 11gm/dl
up to 1 week
Postpartum hemorrhage
Time Frame: up to 1 week
Bleeding from genital tract of 500 mL or more vaginally
up to 1 week
Neonatal weight in kilogram
Time Frame: up to 7 days
categorized as extreme low birth weight (LBW) for <1000 g, very LBW for 1000-1500 g, LBW for 1500-2500 g, and normal birth weight for >2500 g
up to 7 days
Neonatal Apgar(Appearance, Pulse, Grimace, Activity, and Respiration) score
Time Frame: first and fifth minute of life
Apgar scores includes 10 sores , 2 for each . The Apgar score was classified as severely depressed <0-3>, moderately depressed<4-6> and excellent condition<7-10>
first and fifth minute of life
Admission to neonatal care unit in days
Time Frame: up to 7 days
Fetal care unit
up to 7 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Maternal mode of delivery
Time Frame: during labor
Cesarean section or vaginal delivery
during labor

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Diana Y. Rashid, Maternity Teaching Hospital
  • Study Director: Shahla K. Alalaf, Hawler Medical University, College of Medicine

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2016

Primary Completion (Actual)

December 31, 2017

Study Completion (Actual)

December 31, 2017

Study Registration Dates

First Submitted

June 16, 2018

First Submitted That Met QC Criteria

July 16, 2018

First Posted (Actual)

July 18, 2018

Study Record Updates

Last Update Posted (Actual)

July 23, 2018

Last Update Submitted That Met QC Criteria

July 20, 2018

Last Verified

July 1, 2018

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe